Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Slides:

Advertisements

Similar presentations

Volume 53, Issue 3, Pages (March 2008)

Advertisements

Early Detection of Prostate Cancer in 2007

Volume 56, Issue 5, Pages (November 2009)

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Testosterone Therapy in Men With Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 1, Pages (July 2016)

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 73, Issue 6, Pages (June 2018)

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer Jeffrey L. Port, MD, Bhupesh Parashar,

Prostate Cancer Epidemic in Sight?

Volume 74, Issue 4, Pages (October 2018)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 63, Issue 6, Pages (June 2013)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

European Urology Oncology

Prostate Cancer Detection: A View of the Future

Volume 67, Issue 3, Pages (March 2015)

Volume 66, Issue 3, Pages (September 2014)

Volume 67, Issue 6, Pages (June 2015)

Counselling the Prostate Cancer Patient

Volume 66, Issue 6, Pages (December 2014)

Laurent Boccon-Gibod European Urology Supplements

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Prostate Cancer Epidemic in Sight?

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,

Volume 53, Issue 6, Pages (June 2008)

Volume 53, Issue 4, Pages (April 2008)

Trends in Hypospadias Surgery: Results of a Worldwide Survey

Volume 71, Issue 1, Pages (January 2017)

Volume 65, Issue 6, Pages (June 2014)

Volume 74, Issue 2, Pages (August 2018)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era Ryan S. Youland, Miran L. Blanchard, Roxanna Dronca, Lisa Kottschade,

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 74, Issue 6, Pages (December 2018)

European Urology Oncology

Axel Heidenreich European Urology Supplements

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Highlighting Unmet Needs: Real Patients, Difficult Choices

Management of Prostate Cancer: Global Strategies

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

European Urology Oncology

European Urology Oncology

Introduction European Urology Supplements

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew Kneebone, George Hruby, Hannah Ainsworth, Keelan Byrne, Chris Brown, Linxin Guo, Alexander Guminski, Thomas Eade European Urology Oncology Volume 1, Issue 6, Pages 531-537 (December 2018) DOI: 10.1016/j.euo.2018.04.017 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Example of the stereotactic body radiotherapy technique. European Urology Oncology 2018 1, 531-537DOI: (10.1016/j.euo.2018.04.017) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Waterfall plot of the best prostate-specific antigen (PSA) response after stereotactic body radiotherapy (SBRT) compared to baseline by biochemical failure. The change was computed relative to the reading before SBRT and expressed as a percentage. Five bars (with value noted) have been truncated. European Urology Oncology 2018 1, 531-537DOI: (10.1016/j.euo.2018.04.017) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Biochemical failure for the entire cohort. PFS=progression-free survival. European Urology Oncology 2018 1, 531-537DOI: (10.1016/j.euo.2018.04.017) Copyright © 2018 European Association of Urology Terms and Conditions